Document is current
Any future updates will be listed below
-
Authors
ter Avest, Milou M
van Velthoven, Annelieke S M
Speckens, Anne E M
Dijkstra, Gerard
Dresler, Martin
Horjus, Carmen S
Römkens, Tessa E H
Witteman, Ellen M
van Dop, Willemijn A
Bredero, Quirine M
Nissen, Loes H C
Huijbers, Marloes J
-
Funding
Funding for this research was provided by:
ZonMw (555003201)
- License Information
-
More Information
Article History
Received: 10 February 2023
Accepted: 17 March 2023
First Online: 19 June 2023
Declarations
:
: The MindIBD trial has been approved by the ethical review board CMO Arnhem-Nijmegen (#2021–7319; NL75762.091.20). Any significant modifications made to the protocol will be submitted as an amendment to the medical ethics committee and documented in the trial’s registration. The study is conducted according to the principles of the Declaration of Helsinki (6th edition, 2008) and in accordance with the Medical Research Involving Human Subjects Act (WMO). Both verbal and written informed consent are obtained from all study participants (). Participation is free of charge and voluntary, and participants can withdraw from further participation at any time during the study.
: Not applicable.
: The authors declare that they have no competing interests.
